NLO adviseert Precirix bij belangrijke trial mijlpaal

Dit artikel gaat verder in het Engels.

Worldwide, >1.6 m cases of breast cancer and >1.2m cases of gastric cancer are diagnosed annually, of which >20% are HER2-positive. At this moment, there are no approved HER2 targeting radiopharmaceuticals and CAM-H2 is the lead candidate in therapeutic development. 

About Precirix

Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labeled with radioisotopes. 

The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’ technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a higher therapeutic dose for treatment. 

Read more: Precirix dosed first patients in Phase I/II clinical study | Precirix

Image: Precirix.com